Together, our findings uncover a noncanonical carnitine-driven metabolic-epigenetic-immune bypass in MASH-HCC and identify the LINCMD1/DZIP3/OCTN2-L-carnitine axis as a potential therapeutic target. The gene discussed is SLC22A5; the disease is hepatocellular carcinoma.